CARDIFF ONCOLOGY INC (CRDF) Stock News
NASDAQ:CRDF - Nasdaq - US14147L1089 - Common Stock
CRDF Latest News and Analysis
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring...
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments
/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...
What's Going On With Cardiff Oncology Stock On Tuesday?
On Tuesday, Cardiff Oncology, Inc. (NASDAQ:CRDF) revealed initial data from the CRDF-004 Phase 2 trial, which evaluates onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation. Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:
What's Going On With Cardiff Oncology Stock On Tuesday?
Cardiff Oncology's CRDF-004 trial shows promising onvansertib results in RAS-mutated mCRC patients, with higher tumor response rates and a strong safety profile.
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology...
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg...
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line...
CRDF Stock Earnings: Cardiff Oncology Misses EPS, Beats Revenue for Q2 2024
CRDF stock results show that Cardiff Oncology missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
CRDF Stock Earnings: Cardiff Oncology Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cardiff Oncology (NASDAQ:CRDF) just reported results for the second quarter of ...
Cardiff Oncology to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to...
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
/PRNewswire/ -- The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Finding good investing possibilities in the constantly changing stock market might be likened to unearthing buried jewels.
CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024
CRDF stock results show that Cardiff Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cardiff Oncology (NASDAQ:CRDF) just reported results for the first quarter of 2...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients...
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) --...
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in...
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5
For speculators that don’t mind the rumblings of market volatility, these stocks under $5 could be quite attractive.
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to...